Peptide Shows Potential for Treating Eosinophilic Esophagitis in Phase 2 Trial
According to a story from Healio, the pharmaceutical company Revolo Biotherapeutics has been developing '1104, a peptide with a mechanism that 'resets' the immune system to pre-empt the appearance of…